SCHEMBL25625104

SCHEMBL25625104

CNc1nc2[nH]ccc2cc1C(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 4/20 0.45
▸ FEN1 P39748 1/20 0.36
▸ CDK8 P49336 3/20 0.33
▸ AXL P30530 2/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ PIK3CB P42338 1/20 0.33
▸ PIK3CG P48736 1/20 0.33
▸ BRD4 O60885 2/20 0.32
▸ RIPK1 Q13546 1/20 0.32
▸ NUDT1 P36639 1/20 0.32
▸ KDR P35968 2/20 0.31
▸ FGFR1 P11362 1/20 0.31
▸ FYN P06241 1/20 0.31
▸ BPTF Q12830 1/20 0.31
▸ CFTR P13569 1/20 0.30
▸ PLK4 O00444 1/20 0.30
▸ DCLK1 O15075 1/20 0.30
▸ ROCK2 O75116 1/20 0.30
▸ PRKD3 O94806 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613029 0.80 FEN1 (0.39) ULK1FEN1CDK8AXLPIK3CD
SCHEMBL25625964 0.80 ULK1 (0.48) ULK1PAK4SYKIRAK4
SCHEMBL25626044 0.80 NR3C1 (0.43) ULK1FEN1CDK8PIK3CABRD4
SCHEMBL25625108 0.80 PIK3C3 (0.43) ULK1FEN1CDK8RIPK1KDR
SCHEMBL13604904 0.79 CDK8 (0.39) ULK1FEN1CDK8AXLPIK3CD
SCHEMBL25625191 0.79 RIPK1 (0.38) ULK1FEN1CDK8RIPK1KDR
SCHEMBL25625193 0.79 ULK1 (0.36) ULK1FEN1CDK8AXLPIK3CA
SCHEMBL25613108 0.77 ULK1 (0.39) ULK1FEN1CDK8AXLPIK3CD
SCHEMBL25613025 0.77 FEN1 (0.37) ULK1FEN1CDK8AXLPIK3CD
SCHEMBL25613026 0.77 FEN1 (0.42) ULK1FEN1CDK8AXLPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 ULK1 1303/4885FEN1 1864/4885CDK8 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback